Metraipolis › archive › dc_b055dff91ca5

Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report — Europe PMC PMID:42158440

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42158440
DOI
10.3389/fonc.2026.1652716
License (as archived)
solo-consultazione
Archived
2026-11-02T18:47:30.998Z
SHA-256 of the archived text
4242af6858c965a9e1a334e796951d5d27a920a8c2fe629e7088887b41bf4f0e
Stable URL of this page
https://metraipolis.com/documento/dc_b055dff91ca5

How to cite

Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report — Europe PMC PMID:42158440 — Europe PMC (en), https://europepmc.org/article/MED/42158440 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b055dff91ca5 (Metraipolis archive dc_b055dff91ca5, sha256 4242af6858c965a9e1a334e796951d5d27a920a8c2fe629e7088887b41bf4f0e)
BibTeX
@misc{dcb055dff91ca5,
  title = {Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report — Europe PMC PMID:42158440},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42158440},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b055dff91ca5; sha256 4242af6858c965a9e1a334e796951d5d27a920a8c2fe629e7088887b41bf4f0e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42158440. Agents can read the archived copy with the MCP tool read_document.